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Abstract
Background: Mobilization-Observation-Behavior-Intensity-Dementia-2
(MOBID-2) pain scale is a staff-administered pain tool for patients with
dementia. This study explores MOBID-2’s test–retest reliability,
measurement error and responsiveness to change.
Methods: Analyses are based upon data from a cluster randomized trial
including 352 patients with advanced dementia from 18 Norwegian
nursing homes. Test–retest reliability between baseline and week 2
(n = 163), and weeks 2 and 4 (n = 159) was examined in patients not
expected to change (controls), using intraclass correlation coefficient
(ICC2.1), standard error of measurement (SEM) and smallest detectable
change (SDC). Responsiveness was examined by testing six
priori-formulated hypotheses about the association between change scores
on MOBID-2 and other outcome measures.
Results: ICCs of the total MOBID-2 scores were 0.81 (0–2 weeks) and
0.85 (2–4 weeks). SEM and SDC were 1.9 and 3.1 (0–2 weeks) and 1.4 and
2.3 (2–4 weeks), respectively. Five out of six hypotheses were confirmed:
MOBID-2 discriminated (p < 0.001) between change in patients with and
without a stepwise protocol for treatment of pain (SPTP). Moderate
association (r = 0.35) was demonstrated with Cohen-Mansfield Agitation
Inventory, and no association with Mini-Mental State Examination,
Functional Assessment Staging and Activity of Daily Living. Expected
associations between change scores of MOBID-2 and Neuropsychiatric
Inventory – Nursing Home version were not confirmed.
Conclusion: The SEM and SDC in connection with the MOBID-2 pain
scale indicate that the instrument is responsive to a decrease in pain after
a SPTP. Satisfactory test–retest reliability across test periods was
demonstrated. Change scores ≥ 3 on total and subscales are clinically
relevant and are beyond measurement error.
1. Introduction
Undiagnosed and untreated pain is common in nursing
home (NH) patients with advanced dementia. Approxi-
mately 40–80% of these individuals are reported to be
in pain with a substantial need for adequate pain treat-
ment (Corbett et al., 2012). Under-treatment is espe-
cially marked in the presence of frailty, leading to
behavioural disturbances such as agitation (Husebo
et al., 2011a,b; Corbett et al., 2012), depression
(Cohen-Mansfield and Taylor, 1998), anxiety (Arola
et al., 2010) and reduced quality of life (Jakobsson and
Hallberg, 2002; Chen et al., 2003). However, assess-
ment and treatment of pain in dementia is complex
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because persons with memory, language and speech
deficits are unable to communicate clearly about their
pain state, analgesic effects and side effects.
In 2009, the American Geriatric Society recom-
mended a comprehensive, disease-specific assessment
to determine appropriate treatment for each indi-
vidual (American Geriatrics Society Panel on
Pharmacological Management of Persistent Pain in
Older Persons, 2009). Self-reported pain is often
invalid, and pain must therefore be indirectly observed
by proxy raters using a validated pain behaviour
instrument. More than 30 such tools have been devel-
oped, and review articles address the measurement
properties of these instruments and feasibility in clini-
cal practice (Hadjistavropoulos et al., 2007; Herr,
2011; Corbett et al., 2012; Husebo et al., 2012). These
are important steps towards valid proxy rater assess-
ment of pain behaviour in patients with dementia.
The next step to improve treatment is the adminis-
tration of pain medication and evaluation of the effec-
tiveness of this intervention (Corbett et al., 2012).
Thus, the development of a practical and responsive
tool to capture change in pain intensity after pain
treatment is a prerequisite (Terwee et al., 2007).
Recently defined by the COSMIN panel, responsive-
ness is the ‘ability of an instrument to detect change
over time in the construct to be measured’ (Mokkink
et al., 2010). When a gold standard is available, cor-
relations between change scores and the area under
the receiver operator curve (ROC) are considered
(Mokkink et al., 2010). If no gold standard is available,
as is the case with patients with dementia, assessment
of responsiveness relies upon testing hypotheses about
expected correlations between changes in scores of an
instrument and changes in other variables. Although
previous studies report promising results regarding the
responsiveness of pain behaviour tools for patients
with dementia, they are not in line with the method-
ological requirements regarding a priori-formulated
hypotheses, adequate sample size or randomization
process (Morello et al., 2007; Cohen-Mansfield and
Lipson, 2008; Rat et al., 2011).
The Mobilization-Observation-Behavior-Intensity-
Dementia-2 (MOBID-2) pain scale is an observational
pain tool for patients with advanced dementia. Earlier
studies on measurement properties indicated high to
excellent reliability and aspects of validity (Husebo
et al., 2007, 2009, 2010), and MOBID-2 proved to be
feasible for use in clinical practice (Husebo et al., 2008,
2011b). Responsiveness to change has, however, not
been addressed. The aim of this study is to repeat
test–retest reliability and to examine the standard
error of measurement (SEM) and responsiveness to
change in connection with a cluster randomized trial.
2. Methods
2.1 Setting and selection of patients
The study of measurement properties was performed in con-
nection with a cluster randomized controlled trial (RCT) of
the efficacy of pain treatment on behavioural disturbances of
352 NH patients with advanced dementia (Husebo et al.,
2011b). The patients were from 18 NHs in five municipalities
in Western Norway, recruited from October 2009 to June
2010. The patients had lived in the NHs for at least 4 weeks
prior to the trial. They had moderate to severe dementia and
significant behavioural disturbances. The severity of demen-
tia was assessed by a score of ≤19 on the Mini-Mental State
Examination (MMSE) scale (range 0–30) (Folstein et al.,
1975; Burns et al., 2010). Patients were included indepen-
dent of painful diagnoses, presumed pain or ongoing pain
treatment. Dying patients or patients with acute or unstable
psychiatric or medical conditions were not included. The
recruitment strategy, patient samples and design of the study
have been described elsewhere (Husebo et al., 2011b).
2.2 Ethics
Written informed consent included a description of the study
design, benefit and possible side effects of the trial. Since
individuals with mild cognitive impairment have an
impaired capacity to consent to research (Ayalon, 2009),
informed consent was obtained from all patients and all
surrogates/caregivers or the authorized legal representatives.
In accordance with local law, the study was approved by the
Regional Committee for Medical Ethics, Western Norway
What’s already known about this topic?
• Identification and monitoring of pain is challeng-
ing in patients with dementia.
• Efficacy assessment of pain treatment depends
upon the validity of a tool, which should be
responsive to change in pain intensity after pain
treatment.
What does this study add?
• Following the recommendations by COSMIN
panel, MOBID-2 (Mobilization-Observation-
Behavior-Intensity-Dementia-2) pain scale was
tested regarding reliability, standard error of
measurement, smallest detectable change and
responsiveness.
• Indications were provided that MOBID-2 is
responsive to a decrease in pain intensity after
pain treatment over time.
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(REK-Vest 248.08), by the authorized Institutional Review
Board of each participating institution and the Norwegian
Medicines Agency (EudraCTnr: 2008-007490-20). In addi-
tion, the trial is registered at ClinicalTrials.gov
(NCT01021696). The caregivers gave consent to participate
as informants.
2.3 Raters
During the enrolment process, two trained research assis-
tants retrieved data pertaining to background variables,
which included information about gender, age, medical
information (diagnoses and pain diagnoses) and lists of
medication taken (Husebo et al., 2011b). The research assis-
tants did not participate in other data collection during the
intervention study.
Before starting the enrolment process, the patients’
primary caregivers (n = 53), usually a licensed practical
nurse (LPN) who knew the patient at least for the last 4
weeks, learned how to use measurement instruments during
a 2-h education programme. They learned the MOBID-2
procedure by observing video recording of patients with
dementia and by bedside observation of the assessment of
three patients. Efforts were made to keep the patients and
the LPNs uninformed about the study design and type of
intervention. This means that the LPNs were blinded to
group allocation during assessments of the patients.
A consultant for old age psychiatry, an anaesthetist and
pain therapist (B.S.H), one of the research assistants and a
senior member of the NH staff from each institution
reviewed assessment outcomes and drug prescriptions for
each patient after completion of baseline assessment, but
before randomization. In addition, they optimized the
general treatment; this means, for instance, a patient with
symptoms of urinary tract infection received disease-specific
diagnostic and treatment.
Registered nurses, responsible for the documentation, pre-
scribing procedures and distribution of the study medication
during mealtimes, did not participate in data collection of
primary and secondary outcomes. The NH staff were
instructed not to discuss management procedures.
2.4 Examination of reliability and
responsiveness
2.4.1 Test–retest reliability
Patients included in the reliability study were those random-
ized to the control group. It was therefore expected that
these patients would not systematically improve in their pain
state over the time intervals. They were tested with the
MOBID-2 pain scale at baseline (week 0) and at weeks 2 and
4. The reliability was assessed by intraclass correlation coef-
ficient (ICC2.1) using 2-week intervals (0–2 and 2–4 weeks).
Moreover, the SEM and smallest detectable change (SDC)
were estimated. Using both the 2-week intervals enabled us
to assess the stability of our estimates.
2.4.2 Responsiveness
Following the recommendations by the COSMIN panel
(Mokkink et al., 2010), responsiveness was examined by
formulating (a priori) and testing six hypotheses in patients
expected to be in pain (MOBID-2 pain scale total scores ≥ 3)
at baseline.
Hypothesis 1: We hypothesized that pain on the total scale
and on the two subscales would decrease more during the
intervention period of 8 weeks in the intervention patients
who received increased pain medication than in patients
who continued with care and treatment as usual (control
group).
Hypothesis 2: We hypothesized that change in pain scores on
the MOBID-2 pain scale was moderately correlated with
change scores on the Cohen-Mansfield Agitation Inventory
(CMAI) (Cohen-Mansfield and Libin, 2004). It has previ-
ously been shown that untreated pain tends to increase
behavioural disturbances in patients with dementia
(Chibnall et al., 2005; Kovach et al., 2006; Kovacs et al.,
2007). Thus, some behaviours, such as agitation, complain-
ing, pacing or restlessness, may be related to the presence of
pain (Husebo et al., 2011a,b). Pain intensity is, however, a
different phenomenon than frequency of behavioural distur-
bances. Therefore, changes in these observed phenomena
were not expected to be more than moderately correlated.
Hypothesis 3: We hypothesized that change in pain scores on
the MOBID-2 pain scale was moderately correlated with
change scores from the Neuropsychiatric Inventory –
Nursing Home version (NPI-NH) (Selbaek et al., 2008).
Under-treated pain may also increase neuropsychiatric
symptoms in patients with dementia (Manfredi et al., 2003;
Chibnall et al., 2005; Kovach et al., 2006; Corbett et al.,
2012), and there is strong evidence that mood symptoms
such as depression, apathy or nocturnal behaviour are
related to untreated pain (Husebo et al., 2011a,b, 2013). Pain
intensity is, however, a different phenomenon than neuro-
psychiatric symptoms, and changes in these observed phe-
nomena were not expected to be more than moderately
related.
Hypotheses 4–6: We finally hypothesized that change scores
of pain on MOBID-2 pain scale were not correlated with
change scores on measures of the Barthel index of Activity of
Daily Living (ADL) (Mahoney and Barthel, 1965), the
MMSE (Folstein et al., 1975) and the Functional Assessment
Staging (FAST) (Hughes et al., 1982). We suggest that ADL,
MMSE and FAST assess different phenomena than pain,
especially when patients with advanced dementia are
included. We are not aware of pain treatment studies inves-
tigating the effect of analgesics on ADL functioning in NH
patients with severe dementia. However, a recent review of
physical inactivity and its relationship to pain (and vice
versa) found a positive association between ADL and pain in
older person without dementia (Plooij et al., 2012a).
Another study on pain medication prescription and cognitive
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function found no relationship between cognition (assessed
by MMSE) and pain medication (Plooij et al., 2012b).
2.5 Intervention and control (related to
Hypothesis 1)
The patients randomized to the intervention group followed
a stepwise protocol for treatment of pain (SPTP) in accor-
dance with recommendations of the American Geriatrics
Society (American Geriatrics Society Panel on
Pharmacological Management of Persistent Pain in Older
Persons, 2009). Depending upon the ongoing medical treat-
ment, patients in the intervention group received one step
up of increased pain treatment, which might include acet-
aminophen oral (maximum increase to 3 g/day), extended
release morphine oral (maximum 20 mg/day) or pregabalin
oral (maximum 300 mg/day) using a fixed dose regime
(Husebo et al., 2011b). Patients with swallowing difficulties
were treated with buprenorphine transdermal plaster
(maximum 10 μg/h for 7 days). Medication was offered by a
registered nurse at breakfast, lunch and dinner (approxi-
mately 8:00 a.m., noon, 6:00 p.m.), respectively. If needed,
combination therapy was allowed. Patients randomized to
the control groups continued with treatment (including the
ongoing pain treatment) and care as usual.
Related concomitant drugs, anti-dementia medication,
psychotropic drugs, aspirin (one dose per day) or anti-
inflammatory agent (e.g., ibuprofen) was allowed if
remained stable for 4 weeks prior to study inclusion. Use of
as-need analgesics was allowed for all patients and was
monitored during the study. Clinicians were advised when
possible to keep prescriptions and doses of psychotropic
medications unchanged. After the 12-week study period, the
research team and a senior member of the NH staff from each
institution reviewed the last assessment outcomes and drug
prescriptions and optimized pain treatment for all patients.
2.6 Assessment tools (related to demographics
and Hypotheses 2–6)
2.6.1 The MOBID-2 pain scale
Pain was assessed by the MOBID-2 pain scale at weeks 0, 2
and 4 following the MOBID-2 test procedures and guidelines
described earlier (Husebo et al., 2010). In practice, the
assessment of pain was based upon observation of the
patient’s immediate pain behaviour in connection with stan-
dardized, guided movements during morning care
(MOBID-2, part 1, five items) and pain behaviour related to
internal organs, head and skin (MOBID-2, part 2, five items)
monitored over time. Primary caregivers, considered proxy
raters, were encouraged to judge whether the patient’s
behaviour was related to pain or to dementia. For each item,
the caregiver answered the question: ‘How intense do you
consider the pain to be?’ and rated intensity on a numerical
rating scale ranging from 0 (no pain) to 10 (as bad as it possibly
could be) (Jensen et al., 1994). MOBID-2 parts 1 and 2 and
the total MOBID-2 scores are derived from the caregiver by
overall intensity scores.
Test–retest reliability and inter- and intra-rater reliability
of the MOBID-2 pain scale have been examined in previous
studies, but different samples and time between assessments
were applied (Husebo et al., 2007, 2009, 2010). In a study
including 77 patients with severe dementia from one NH, the
inter-rater and test–retest reliability (after 1 day) for pain
intensity of items, subscales and total scale were mostly very
good, with ICCs ranging from 0.80 to 0.94 and from 0.60 to
0.94, respectively (Husebo et al., 2010).
2.6.2 Cohen-Mansﬁeld Agitation Inventory
The CMAI is a 29-item instrument (range 29–203 points)
used by caregivers to rate the frequency with which NH
patients with dementia manifest aggressive behaviour,
physical non-aggressive behaviour or verbally agitated
behaviour (Cohen-Mansfield and Libin, 2004). Behavioural
disturbances were defined by a score of ≥39. CMAI items are
rated on a 1- to 7-point scale of frequency, ranging from
never (1); occurring less than once a week (2); once or twice
a week (3); several times a week (4); once or twice a day (5);
several times a day (6); to several times an hour (7). Good
reliability and validity has been reported (Cohen-Mansfield
and Libin, 2004). The rating was made by a trained research
assistant based upon a face-to-face interview with the care-
giver who was familiar with the patient.
2.6.3 Neuropsychiatric Inventory – Nursing
Home version
The NPI-NH is a 12-item instrument (range 0–144 points)
developed to assist caregivers to rate the frequency and
severity with which NH patients with dementia manifest
neuropsychiatric symptoms such as delusions, hallucina-
tions, agitation, depression, anxiety, euphoria, apathy, disin-
hibition, irritability, aberrant motor behaviour, nocturnal
behaviour, appetite and eating disorders (Selbaek et al.,
2008). NPI-NH items are rated on a 1- to 4-point scale of
frequency, ranging from (1) occasionally – less than once per
week; (2) often – approximately once per week; (3) fre-
quently – several times a week but less than every day; (4)
very frequently – daily or essentially continuously present.
The severity is rated as (1) mild – produces little distress in
the patient; (2) moderate – more disturbing to the patient
but can be redirected by the caregiver; (3) severe – very
disturbing to the patient and difficult to redirect. Good reli-
ability and validity of the Norwegian version of NPI-NH has
been reported (Selbaek et al., 2008).
2.6.4 Barthel index of Activity of Daily Living
The Barthel ADL (range 0–20) evaluates the patient’s physi-
cal function, which includes daily activities such as feeding,
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moving, personal toilet and dressing (Mahoney and Barthel,
1965). The severity of functional impairment is rated as mild
(12–20), moderate (9–10), severe (5–8) and very severe (<5).
Reliability has been assessed thoroughly by self-report, by
trained nurses and two independent skilled observers.
Agreement was generally present in more than 90% of situ-
ations. Validity, reliability, sensitivity and clinical utility were
excellent (Sheikh et al., 1979; Collin et al., 1988). Higher
values indicate higher levels of activities of daily functioning
and independence.
2.6.5 Mini-Mental State Examination
The MMSE is a 30-point scale that enables cut-off differen-
tiation for levels of severity of cognitive impairment (i.e.,
0–11 = severe, 12–17 = moderate, 18–23 = mild, 24–30 = no
impairment) (Folstein et al., 1975). The questionnaire con-
sists of several orientation question (10 points), registration
and recall task (6), attention task (5), three-stage command
(3), two naming tasks (2), repetition task (1), reading com-
prehension task (1), written sentence (1) and a visual con-
struction (1). In this study, cognitive impairment was
categorized as follows: moderate (MMSE score ≤ 19) and
severe (MMSE score ≤ 12) (Burns et al., 2010).
Earlier reports suggested a cut-off point of 23/24 on the
MMSE scale to be able to discriminate between patients with
cognitive impairment and normal subjects (Folstein et al.,
1975). However, latter studies found that the specificity of
the MMSE was lower for individuals with less schooling and
for those over the age of 65 (Mitchell, 2009). In addition,
differences in application of the MMSE between primary
care, memory clinic and community settings are obvious. To
be sure to include patients with dementia in this study, we
chose the latest recommendation by Burns et al., who cat-
egorized MMSE scores as having normal, mild, moderate
(MMSE score ≤ 19) and severe (MMSE score ≤ 12) (Burns
et al., 2010).
2.6.6 Functional Assessment Staging
FAST describes a continuum of seven successive stages and
sub-stages from normality to most severe dementia (Hughes
et al., 1982). Moderate to severe dementia is consistent with
FAST stages of 5 or 6 or 7. Stage 5 is defined as moderately
severe cognitive decline, with deficient performance in
activities of daily living such as choosing proper clothing and
maintaining hygiene. Stage 6 is defined as severe cognitive
decline with incontinence and decreased ability to clothe,
bathe, toilet oneself, severely limited speech, vocabulary and
emotional expression. A patient who is considered to be at
FAST stage 7 is no longer able to talk or smile, to walk and
hold up her head. MMSE and FAST was used at weeks 0 and
8.
2.7 Analysis
Descriptive statistics was used to describe demographic char-
acteristics and test scores of the study samples. Statistical
analyses were performed using the software program SPSS
17.0 (SPSS, Inc., Chicago, IL, USA).
Test–retest reliability was calculated using ICC2.1 between
ratings at weeks 0 and 2, and between weeks 2 and 4. Each
single MOBID-2 item of parts 1and 2 and the total MOBID-2
pain scale score were analysed. ICC2.1 is a two-way mixed,
absolute agreement model, also including variance due to
systematic difference in the error variance (van der Roer
et al., 2006). The SEMAGREEMENT was estimated by taking the
square root of the within-subject variance consisting of vari-
ance between the measures plus the residual variance. The
SDC was calculated as SEMAGREEMENT × √2 × 1.64 (van der
Roer et al., 2006; Kovacs et al., 2007), and is the test value
that a patient must exceed to demonstrate an improvement
above measurement error with 95% certainty (Bland and
Altman, 1996).
Regarding responsiveness, Hypothesis 1 was examined by
paired samples t-test. The 0-hypothesis of no difference in
change between the two groups was examined by indepen-
dent samples t-test, p ≤ 0.05.
The hypothesis of moderate correlation (0.50 > r ≥ 0.30;
Pallant, 2005) between change scores of the total MOBID-2
pain scale versus CMAI (Hypothesis 2) and NPI-NH (Hypoth-
esis 3) and weak or no correlation (r < 0.30) between total
change scores of the MOBID-2 pain scale versus measures of
ADL, MMSE and FAST (Hypotheses 4–6) were examined by
Pearson’s correlation.
3. Results
3.1 Demographics
At baseline, 163 patients who were not expected to
change (control group) were included in the test–
retest reliability study, and 203 patients with
MOBID-2 pain scale scores ≥ 3 participated in the
responsiveness study; 99 patients from the control
group and 104 from the intervention group.
The demographic and test characteristics of the
patients at baseline are shown in Table 1. These char-
acteristics were rather similar in patients included in
the reliability and responsiveness studies; most were
women, 78% and 74%, with a mean age of 87 and 85
years, respectively. During the 8 weeks, 20 and 28
patients were lost in the control and the SPTP groups,
respectively (p = 0.298) (Husebo et al., 2011b). There
were 14 deaths during the study period: 8 in the
control and 6 the intervention group.
3.2 Clinical pain scores in NH patients
with dementia
As expected, the mean MOBID-2 pain scale total
scores were higher at baseline in the responsiveness
study (mean score 5.4) than in the reliability study
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(mean score 3.7) (Table 2). Guided movements of the
hips, knees and ankles and turning over in bed were
the most painful items related to the musculoskeletal
system, MOBID-2 part 1. The most painful locations
that might be related to internal organs, head and skin
(MOBID-2 part 2) were the areas for the pelvis and
genital organs. Table 2 shows the scores of single
MOBID-2 pain scale items and total score.
3.3 Reliability and measurement error
Test–retest reliability between baseline and 2 weeks
was high for the separate items (ICC2.1 = 0.731–0.857)
and the total score (ICC2.1 = 0.805). Between weeks 2
and 4, reliability was even better for the separate items
(ICC2.1 = 0.729–0.889) and for the total score
(ICC2.1 = 0.852) (Table 3). The SEM and the SDC for
the MOBID-2 total score improved from 1.9 and 3.1
(0–2 weeks) to 1.4 and 2.3 (2–4 weeks) over time.
3.4 Responsiveness
Supporting our first hypothesis, patients randomized
to stepwise pain treatment improved more on
MOBID-2 pain scale for single items, MOBID-2 parts 1
and 2, and on the total score than did the control
group that received treatment and care as usual. Test
scores for the two groups are shown in Table 4 and
demonstrate a mean improvement on MOBID-2 total
score of 1.7 in the intervention group and 0.3 in the
control group. The difference in change was found to
be statistically significant, in favour of the intervention
group for MOBID-2 part 1 (p < 0.001), MOBID-2 part
2 (p < 0.001) and MOBID-2 total score (p < 0.001).
Table 1 Demographic and clinical characteristics of patients who completed MOBID-2 pain score at baseline and participated in the study of test–retest
reliability (control patients) and responsiveness (patients with MOBID-2 scores ≥ 3).
Rest–retest reliability (n = 163) Responsiveness (n = 203)
Female, n (%) 128 (78) 149 (74)
Age (years), mean (SD) 86.5 (6.7) 85.4 (6.9)
MOBID-2 pain scale,a mean (SD) 3.7 (2.4) 5.4 (1.8)
CMAI,b mean (SD) 56.1 (16.0) 56.2 (14.5)
NPI-NH,c mean (SD) 31.4 (21.4) 34.5 (21.7)
FAST,d mean (SD) 6.0 (0.7) 6.0 (0.7)
MMSE,e mean (SD) 8.4 (6.7) 8.1 (6.7)
ADL,f mean (SD) 8.6 (5.6) 7.6 (5.6)
ICD diagnoses 5.4 (2.1) 5.6 (2.0)
aMobilization-Observation-Behavior-Intensity-Dementia-2 pain scale (range 0–10); higher scores mean more pain.
bCohen-Mansﬁeld Agitation Inventory (range 29–203); higher scores mean more agitation (scores ≥ 39 usually accepted as clinically signiﬁcant).
cNeuropsychiatric Inventory – Nursing Home version (range 1–144); higher scores mean more psychiatric symptoms.
dFunctional Assessment Staging (range 1–7); higher scores mean more cognitive impairment.
eMini-Mental State Examination (range 0–30); higher scores mean more cognitive impairment.
fActivities of Daily Living (range 0–20); higher scores mean higher physical function.
Table 2 Pain scores on MOBID-2 single items and total scores of patients who participated in the reliability study (controls with no intervention) and in
the responsiveness study (MOBID-2 ≥ 3).
Reliability (n = 163)
MOBID-2, mean (SD)
Responsiveness (n = 203)
MOBID-2 ≥ 3, mean (SD)
1. Hands 0.8 (1.9) 1.4 (2.3)
2. Arms 1.7 (2.3) 2.4 (2.7)
3. Legs 2.6 (2.9) 3.3 (3.0)
4. Turn over 1.9 (2.5) 2.9 (2.9)
5. Sit 1.6 (2.2) 2.6 (2.8)
6. Head, mouth, neck 1.0 (1.8) 1.7 (2.3)
7. Heart, lung, chest wall 0.8 (1.7) 1.1 (1.9)
8. Abdomen 0.9 (1.8) 1.3 (2.1)
9. Pelvis, genital organ 1.6 (2.5) 2.4 (2.9)
10. Skin 1.7 (2.3) 2.3 (2.7)
11. Overall pain score 3.7 (2.4) 5.4 (1.8)
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Our second hypothesis was confirmed as we found
a moderate association between change scores of
MOBID-2 pain scale and change scores of CMAI
(n = 90) in the intervention group after 8 weeks. Our
third hypothesis was not confirmed as we found only
a weak association between change scores of
MOBID-2 and NPI-NH (Table 5). Hypotheses 4–6 were
confirmed as there was no correlation between change
scores on MOBID-2 pain scale and change scores on
ADL, MMSE and FAST in the intervention group
(Table 5).
4. Discussion
In this study, we assessed the following measurement
properties of the MOBID-2 pain scale in NH patients
with advanced dementia: test–retest reliability, SEM
and responsiveness to change. The study was planned
and data were collected alongside a large cluster ran-
domized clinical trial (Husebo et al., 2011b). Reliabil-
ity values by ICCs were found to be high for both time
intervals of 2 weeks. As the patients randomized to
control received treatment and care as usual, they
were not expected to change systematically. Measure-
ment error by SEM and SDC values ranged between
1.4 and 1.9 and 3.1 and 2.3, respectively. This indicates
that a decrease of at least 3 on the 0–10 point total
MOBID-2 pain scale is needed to be confident that an
improvement in individual patients is not merely a
measurement error.
Further, we found evidence that the total MOBID-2
pain scale is responsive to a decrease in pain. The
hypothesis that patients with pain who received step-
Table 3 Test–retest reliability of MOBID-2 pain scale data between base-
line (week 0) and week 2, and weeks 2 and 4 by intraclass correlation
coefﬁcient (ICC2,1), standard error of measurement (SEM) and smallest
detectable change (SDC), assessed in controls who received treatment as
usual.
Weeks 0–2 (n = 163) Weeks 2–4 (n = 159)
ICC2.1 SEM SDC ICC 2.1 SEM SDC
1. Hand 0.852 1.1 1.8 0.889 0.9 1.4
2. Arms 0.731 1.6 2.6 0.785 1.4 2.3
3. Legs 0.820 1.6 2.6 0.879 1.2 1.9
4. Turn over 0.841 1.3 2.1 0.827 1.3 2.1
5. Sit 0.813 1.2 1.9 0.828 1.2 1.9
6. Head, mouth, neck 0.760 1.1 1.8 0.729 1.1 1.8
7. Heart, lung, chest wall 0.811 0.9 1.4 0.861 0.7 1.1
8. Abdomen 0.757 1.1 1.8 0.815 0.9 1.4
9. Pelvis, genital organs 0.732 1.6 2.6 0.855 1.2 1.9
10. Skin 0.857 1.2 1.9 0.822 1.3 2.1
MOBID-2 total score 0.805 1.9 3.1 0.852 1.4 2.3
Ta
b
le
4
Te
st
sc
or
es
of
si
ng
le
M
O
B
ID
-2
ite
m
s,
M
O
B
ID
-2
p
ar
ts
1
an
d
2,
an
d
M
O
B
ID
-2
to
ta
ls
co
re
at
b
as
el
in
e
an
d
at
w
ee
k
8
fo
r
p
at
ie
nt
s
w
ith
p
ai
n
at
b
as
el
in
e
(M
O
B
ID
-2
≥
3)
,a
nd
d
iff
er
en
ce
in
sc
or
e
ch
an
ge
s
in
co
nt
ro
ls
re
ce
iv
in
g
tr
ea
tm
en
t
as
us
ua
la
nd
in
p
at
ie
nt
s
re
ce
iv
in
g
in
cr
ea
se
d
p
ai
n
tr
ea
tm
en
t
(in
te
rv
en
tio
n)
.
It
em
C
on
tr
ol
(n
=
99
)
In
te
rv
en
tio
n
(n
=
10
4)
D
iff
er
en
ce
in
ch
an
ge
p
-v
al
ue
b
B
as
el
in
e,
m
ea
n
(S
D
)
W
ee
k
8,
m
ea
n
(S
D
)
C
ha
ng
e,
a
m
ea
n
(S
D
)
B
as
el
in
e,
m
ea
n
(S
D
)
W
ee
k
8,
m
ea
n
(S
D
)
C
ha
ng
e,
a
m
ea
n
(S
D
)
1.
H
an
d
s
1.
2
(2
.3
)
1.
2
(2
.3
)
0.
0
(1
.2
)
1.
5
(2
.3
)
1.
0
(1
.8
)
0.
4
(2
.1
)
0.
57
7
2.
A
rm
s
2.
5
(2
.7
)
2.
4
(2
.8
)
0.
1
(2
.6
)
2.
5
(2
.8
)
1.
3
(2
.0
)
1.
1
(2
.4
)
0.
00
5
3.
Le
gs
3.
7
(3
.1
)
2.
9
(2
.9
)
0.
9
(2
.8
)
2.
9
(2
.9
)
2.
0
(2
.2
)
0.
8
(3
.0
)
0.
03
2
4.
Tu
rn
ov
er
2.
8
(2
.8
)
2.
6
(2
.7
)
0.
3
(2
.6
)
3.
0
(2
.9
)
1.
6
(2
.0
)
1.
3
(2
.7
)
0.
01
3
5.
Si
t
2.
2
(2
.3
)
2.
3
(2
.5
)
−0
.2
(2
.1
)
3.
1
(3
.1
)
1.
6
(2
.0
)
1.
5
(1
,3
)
0.
02
7
6.
H
ea
d
,m
ou
th
,n
ec
k
1.
3
(2
.1
)
1.
0
(2
.0
)
0.
3
(1
.6
)
1.
8
(2
.4
)
0.
8
(1
.6
)
1.
0
(2
.5
)
0.
52
3
7.
H
ea
rt
,l
un
g,
ch
es
t
w
al
l
1.
1
(2
.0
)
1.
1
(1
.8
)
0.
0
(1
.7
)
1.
1
(1
.9
)
0.
5
(1
.2
)
0.
6
(1
.7
)
0.
01
1
8.
A
b
d
om
en
1.
1
(2
.1
)
0.
9
(1
.8
)
0.
1
(0
.2
)
1.
4
(2
.1
)
0.
4
(1
.0
)
1.
0
(2
.3
)
0.
02
9
9.
Pe
lv
is
,g
en
ita
lo
rg
an
2.
0
(2
.8
)
2.
0
(2
.6
)
0.
1
(3
.0
)
2.
5
(2
.9
)
0.
9
(1
.6
)
1.
6
(2
.5
)
0.
00
3
10
.
Sk
in
2.
3
(2
.6
)
1.
9
(2
.7
)
2.
2
(2
.8
)
1.
1
(2
.8
)
1.
1
(1
.9
)
1.
0
(3
.1
)
0.
04
7
M
O
B
ID
-2
p
ar
t
1
(it
em
s
1-
5)
5.
0
(2
.7
)
4.
5
(2
.9
)
0.
5
(2
.8
)
4.
8
(2
.8
)
2.
8
(2
.4
)
2.
0
(3
.2
)
<0
.0
01
M
O
B
ID
-2
p
ar
t
2
(it
em
s
6-
10
)
4.
2
(2
.7
)
3.
8
(2
.9
)
0.
4
(2
.8
)
4.
6
(2
.5
)
2.
4
(2
.2
)
2.
2
(3
.1
)
<0
.0
01
M
O
B
ID
-2
to
ta
lp
ai
n
sc
or
e
5.
3
(1
.8
)
4.
3
(2
.5
)
1.
0
(2
.2
)
5.
4
(2
.0
)
2.
6
(2
.1
)
2.
7
(2
.7
)
<0
.0
01
a S
tu
d
en
t’
s
p
ai
re
d
sa
m
p
le
t-
te
st
;c
ha
ng
e
fr
om
b
as
el
in
e
to
w
ee
k
8.
b
In
d
ep
en
d
en
t-
sa
m
p
le
s
t-
te
st
;d
iff
er
en
ce
in
ch
an
ge
b
et
w
ee
n
gr
ou
p
s.
B.S. Husebo et al. MOBID-2 responsiveness
© 2014 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of
European Pain Federation - EFIC®
Eur J Pain 18 (2014) 1419–1430 1425
wise increased pain medication over time obtained
more pain relief than did patients who received treat-
ment and care as usual was confirmed. This difference
in change between the patient groups also applied to
MOBID-2 parts 1 and 2, and to most of the single
MOBID-2 items. Other hypotheses exploring the
responsiveness (longitudinal validity) provided evi-
dence that a decrease in total MOBID-2 pain scale
scores reflects a decrease in aspects related to pain.
Results support the instrument’s ability to act as an
outcome measure of pain in efficacy studies of pain
treatment including patients with advanced dementia.
This is of key importance because a central step to
ensure improved pain management in patients with
dementia is the ability of a pain tool to capture the
effect of pain treatment over time.
The association between MOBID-2 pain scale and
CMAI was, as expected, moderately and confirmed
our hypothesis. Pain behaviour certainly includes ele-
ments of behavioural disturbances in patients with
dementia, and earlier findings demonstrated reduc-
tions in agitation and aggression by systematic pain
management in patients with dementia (Husebo et al.,
2011b). Especially, verbal agitation behaviours, such
as complaining or negativism, and physical non-
aggressive behaviour, such as pacing and restlessness,
responded to this treatment (Husebo et al., 2013).
Testing the hypothesis of correlation between
change scores of MOBID-2 and scores of NPI-NH
turned out to be lower than expected and demon-
strated only weak correlation. Thus, a change in pain
scores seems to be a different phenomenon than
changes in the overall score of NPI-NH, which, besides
agitation and mood syndrome, also includes psychiat-
ric symptoms such as delusions, hallucinations or
disinhibition.
For MMSE and ADL, we found, as expected, that
changes in pain is truly a different phenomenon than
changes in scores on ADL functioning or cognition. It
has been suggested earlier that patients exhibit higher
levels of general activity during treatment with acet-
aminophen (Chibnall et al., 2005). However, the
sample size of that study was quite small (n = 25) and
the ADL index was used as an outcome measure.
More detailed analyses are needed to investigate the
impact of different analgesic groups on ADL function-
ing and cognition in patients with advanced dementia.
4.1 Pain frequency and location
Our data confirm that pain is still a frequent symptom
in NH patients with dementia. Sixty-two percent of
the sample was found to be in pain defined as
MOBID-2 pain scale scores ≥ 3. A previous cross-
sectional study from a NH with a high focus upon
palliative care, with physicians and caregivers skilled
in pain treatment, reported a pain prevalence of 54%
(Husebo et al., 2007). Supporting previous results,
most frequent and painful were mobilizing the hips
and legs (Husebo et al., 2010). As the most common
clinical syndromes involving somatic nociceptor
activities are associated with degenerative diseases or
other painful conditions in muscles, bone and/or
joints, gently guided movements, for instance, per-
formed during morning care, should be part of a
routine assessment protocol to reveal musculoskeletal
pain in these individuals (Husebo et al., 2010; Corbett
et al., 2012). Pain from internal organs, head and skin
was less frequently observed; most frequent were
painful conditions in the pelvis and/or genital organs
and pain that might originate from the skin. In
general, pain seemed attributed mainly to the muscu-
loskeletal system. In general, diagnosing the type of
pain, i.e., nociceptive, peripheral and central neuro-
pathic syndrome, remains extremely difficult, espe-
cially in patients in an advanced stage and it was
recently suggested that central neuropathic pain is by
far the most under-treated type of pain in patients
with dementia (Scherder and Plooij, 2012).
Table 5 Testing hypothesis of correlation (Pearson, r) between change scores ofMOBID-2 and change scores of CMAI, NPI-NH, FAST,MMSE andADL after
8 weeks of pain treatment, n = 104.
Measurement MOBID-2 Expected range in correlation Hypothesis conﬁrmed?
CMAI 0.351* 0.60 > r ≥ 0.30 Yes
NPI-NH 0.275* 0.60 > r ≥ 0.30 No
FAST −0.030 r < 0.20 Yes
MMSE −0.089 r < 0.20 Yes
ADL −0.081 r < 0.20 Yes
ADL, Activities of Daily Living; CMAI, Cohen-Mansﬁeld Agitation Inventory; FAST, Functional Assessment Staging; MMSE, Mini-Mental State Examination;
MOBID-2, Mobilization-Observation-Behavior-Intensity-Dementia-2 pain scale; NPI-NH, Neuropsychiatric Inventory – Nursing Home version.
*p < 0.001.
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4.2 Reliability and measurement error
Sufficient test–retest reliability is a prerequisite for
responsiveness to change of a measure (Terwee et al.,
2007; Strand et al., 2011). High to excellent inter- and
intra-tester and test–retest reliability of the MOBID-2
has been demonstrated in previous studies based upon
scores from both video recordings and bedside care
situations in patients with severe dementia (Husebo
et al., 2009, 2010). Compared with these studies, test–
retest reliability values of the present study were
somewhat less favourable, probably due to the longer
time interval applied. Although the patients received
treatment and care as usual, their conditions might
still fluctuate over time, and pain medication or other
treatments might be initiated or terminated during the
time periods of 2 weeks between the assessments. The
most important information derived from this study is
the SDC, finding that a decrease of at least 3 on the
0–10 point total MOBID-2 pain scale is needed to
demonstrate a change above measurement error in
individual patients. Taking the two test periods into
consideration, we find the stability of reliability esti-
mates to be satisfactory.
It is noteworthy that the test–retest reliability of the
item for head, mouth and neck was low. In addition,
this item did not seem responsive to change after
individual pain treatment. Orofacial pain is a complex
clinical symptom of temporomandibular disorders
characterized by a reduction of chewing ability. In
turn, impaired chewing may result in chronic malnu-
trition, vitamin deficiency and poorer physical activi-
ties (Lobbezoo et al., 2011). A recent review article
presents the complexity of this vicious circle and
underlines the needs for the development and testing
of a new tool that can help dentists in the diagnosis of
orofacial and dental pain in this vulnerable patient
population (Lobbezoo et al., 2011). It is questionable
whether the MOBID-2 pain scale can be further devel-
oped to cover all different aspects of pain, such as
orofacial pain and neuropathic pain in patients with
diabetes or after stroke. The European COST-Action
TD 1005, Assessment of Pain in Patients with Cognitive
Impairment, especially Dementia, is presently working on
the development of a comprehensive and internation-
ally agreed-on assessment toolkit for older adults tar-
geting the various aspects of pain and different pain
diagnoses.
4.3 Responsiveness
Three other studies had previously investigated the
responsiveness of pain tools for patients with demen-
tia or non-verbally communicating elderly.
Cohen-Mansfield and Lipson (2008) compared the
responsiveness of six inform rating and observation
pain tools in order to assess pain treatment effect in 36
patients with dementia. Another subsequent trial of
pain treatment in non-verbally communicating
elderly by Morello et al. (2007) reported very good
responsiveness of the Elderly Pain Caring Assessment
(EPCA-2) after pain intervention in 283 non-verbally
communicating elder patients. The third study by Rat
et al. (2011) included 91 acute pain patients with an
inability to communicate verbally, to investigate the
responsiveness of the Algoplus®.
Although these studies report promising results, the
methodological approaches are questionable in light of
the latter requirements by the COSMIN group, which
recommends a checklist for assessing the method-
ological quality of health status measurement instru-
ments (Mokkink et al., 2010). Following this, none of
these studies examined measurement error by the
SEM and the SDC, important parameters for judging
change scores. In studies without an available gold
standard, responsiveness measures cannot be based
upon a ROC analysis, but rather on hypotheses about
changes in scores formulated a priori. Some of the
studies were underpowered, lack a sample sizes calcu-
lation or drop-out rate, and/or control groups to
compare changes over time with the intervention
groups. Individual pain treatment is necessary to
obtain relevant change scores, but interventions are
often not described precisely.
Until recently, there was no consensus in the
research literature on what constitutes a responsive
measure and how responsiveness should be examined
and quantified. Based upon a Delphi process, the
COSMIN group concluded that responsiveness relies
upon differences between changes in scores, or
expected correlations between changes in scores on
the respective instrument, and other instruments
known to have adequate responsiveness (Mokkink
et al., 2010). In the current study, we followed the
recommendations of the American Geriatrics Society
for pharmacological management of persistent pain in
older persons and presumed pain medication as a gold
standard for change in pain (American Geriatrics
Society Panel on Pharmacological Management of
Persistent Pain in Older Persons, 2009). Thus, when
testing our first hypothesis, we expected more
decrease in pain in patients with pain who received
increased pain medication, compared to those who
continued with treatment and care as usual. This
hypothesis was confirmed as the intervention group
obtained a mean pain decrease of 2.7 on the 10 point
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total MOBID-2 pain scale, while it decreased by only a
mean of 1.0 in the control group.
4.4 Ethical considerations
It may be an ethical concern that patients randomized
to control were not treated at once in according with
a stepwise protocol for treating pain by the research
team. The risk associated with individual or cluster
randomization is particularly great when the interven-
tion group receives important treatment such as pain
management. The challenge of designing an ethical
randomized trial requires balancing the potential ben-
efits and risk of harm faced by individual participation
with the potential long-term benefit to those subjects
and to society at large (Donner and Klar, 2000).
Thereby, clinical trials should meet the criteria of
minimal risk, which means that the probability and
magnitude of harm or discomfort anticipated are not
greater than those ordinarily encountered in daily life
or during the performance of routine physical exami-
nations or tests (US Federal Government – Office for
Protection from Research Risks, 1994).
Concerning the risk/benefit ratio of the control
group in the present study, we attempted to ensure
that participants benefitted by participation in this
study. All patients received optimized treatment by an
expert group based upon data collected during enrol-
ment and before randomization, as well as after the
end of the study. This means that the patients were
taken better care of regarding pain treatment than if
they had not participated in the study. Use of as-need
analgesics was allowed for all patients and none were
removed from their ongoing pain treatment. NH staff
improved their knowledge regarding pain assessment
and –treatment by standardized education.
4.5 Limitations of the study
The current RCT study is the first adequately powered
parallel group RCT of pain management for patients
with advanced dementia, providing a good basis for
this responsiveness study, and following the latest
COSMIN recommendations as to how measurement
properties should be examined. However, our study
has several limitations. The COSMIN checklist has not
yet been reliability tested and some of the standards
need further refinement, e.g., by defining an adequate
sample size or test–retest time interval or when some-
thing is adequately described (Mokkink et al., 2010).
In this study, pain improved in both intervention and
control clusters (Husebo et al., 2011a). That may indi-
cate a Hawthorne effect perhaps related to increased
staff competence and training. However, use of
as-need analgesics was allowed for all patients and
should have been monitored more closely during the
study. Precautions were taken to blind research assis-
tants and primary caregivers for group allocation, but
despite these efforts, fully blind these studies will
always be difficult because of the whole NH setting.
Although enormous under-treatment of pain is still
a challenge in NH patients with dementia (Husebo
et al., 2008; Plooij et al., 2012b), these individuals are
at high risk for poly-pharmacy and related side effects.
Recent literature indicate that analgesic use is almost
higher among people with dementia compared with
older adults without dementia, although the majority
of these studies were undertaken in Scandinavia and
may not be indicative of treatment elsewhere
(Lovheim et al., 2008; Haasum et al., 2011). The fre-
quency of analgesic prescription does not necessarily
indicate whether an appropriate analgesic treatment is
being prescribed to the right people at the right time
(Corbett et al., 2012). Among individuals with demen-
tia, this will depend, to a great extent, upon the timely
identification and assessment of pain and pain treat-
ment effect. In these patients, we must find the
balance between effect and side effect, as they are
unable to report neither pain nor the effect of pain
management or side effects of poly-pharmacy.
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